Eli Lilly (LLY) stock has been moving on a flurry of early June catalysts, including strong late stage data for obesity drug retatrutide, progress for oral GLP-1 Foundayo, and an FDA-approved, less frequent Ebglyss regimen.

The recent clinical and regulatory news flow is feeding into strong momentum, with Eli Lilly’s 30 day share price return of 17.28% sitting against a 1 year total shareholder return of 43.98% and a very large 5 year total shareholder return, all at a latest share price of US$1,160.95.

If obesity and diabetes breakthroughs have caught your attention, it can be worth widening the lens to other healthcare related AI opportunities using our 40 healthcare AI stocks.

With Eli Lilly’s shares already up 44% over the past year and trading just below the average analyst target, the key question is whether recent obesity and diabetes wins still leave potential upside, or if the stock is already pricing in future growth.

Most Popular Narrative: 21.4% Undervalued

According to the widely followed narrative from AHaron, the fair value of Eli Lilly at $1,477.03 sits well above the last close at $1,160.95. This frames the current debate around how much of the growth story is already reflected in the price.

You are buying a business already growing at 25% annually, with its most important new drug not yet approved and not yet reflected in any revenue number, at a price that a conservative model says is 27 to 32% below fair value. The pricing headwinds are real, but they are happening to a company with manufacturing scale, regulatory depth, and a next-generation compound that has already beaten the highest analyst expectations in Phase 3. That is the story. Everything after this is just watching the trial readouts come in.

Want to see how this fair value is built? The narrative leans on fast scaling obesity revenue, firm profit margins and a future earnings multiple more common in high growth tech. Curious which exact assumptions drive that gap to $1,477.03 and how they compound over time? The full narrative lays out the numbers behind this pricing argument in detail.

Result: Fair Value of $1,477.03 (UNDERVALUED)

However, the story can shift quickly if obesity drug pricing comes under heavier pressure, or if key late stage trial results for retatrutide disappoint.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Check: High Price Tag On Earnings

The narrative model suggests Eli Lilly is 21.4% undervalued, but the market is asking a premium on earnings. The stock trades on a 41x P/E versus 15.1x for the US pharmaceuticals industry, 24.1x for peers, and a fair ratio of 35.6x that the market could move toward over time.

That gap means investors are paying more for each dollar of current earnings than both peers and the fair ratio imply, which can reduce room for error if growth or pricing proves softer than expected. It raises a simple question for you as a shareholder: How confident are you that Eli Lilly can keep justifying this premium?

Next Steps

With bullish narratives, pricing concerns, and both risks and rewards on the table, this is the moment to look through the data yourself, decide where you stand, and then weigh up the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just Eli Lilly, you could miss other stocks that fit your style. Use the screeners below to keep building your watchlist intelligently.

• Target potential mispricings by scanning a curated set of 46 high quality undervalued stocks that combine quality with prices that may not fully reflect their fundamentals yet.
• Prioritize resilience by reviewing 67 resilient stocks with low risk scores that score well on risk factors, helping you focus on durability when conditions change.
• Get ahead of the crowd by checking a screener containing 20 high quality undiscovered gems before wider attention arrives so you are not reacting only after the story is obvious.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.